SEARCH · PubMed Health

Results for “Transurethral Resection of Bladder”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 73 records · Page 4Linked to original sources

PubMed1990

[Treatment of PT1 tumors of the bladder using transurethral resection and intravesical immunotherapy].

Twenty-six patients with a PT1 urothelial bladder tumour were treated by transurethral resection and endovesical BCG. The authors compared previously untreated patients with patients with a history of bladder tumour present for an average of 4.6 years. The results of this study show that 72% of bladders in the first group were preserved compared with 53% in the second group. 45% of patients in whom the tumour invaded the superficial lamina propria developed a recurrence compared with 100% of tumours with invasion of the deep lamina propria. 25% of patients who developed a recurrence died in the course of this study.

Administration, Intravesical↗

PubMed1976

[Transurethral resection of bladder neoplasms].

The technique of removal of bladder tumours is discussed on the basis of experience with transurethral resection performed on 200 patients suffering from bladder tumour (113 benign and 87 malignant tumours). The indications for the intervention are as follows. With benign tumours, resection has to be given preference over exposure. When malignant tumours are operable and situated on the mobile part of the bladder, radical surgery is recommended. When the tumour is in some other position, transurethral resection is the procedure of choice.

Female↗

PubMed2026

Intravesical mitomycin-C administered immediately before transurethral resection of bladder tumor in non-muscle-invasive bladder cancer: Clinical outcomes and molecular predictors from over 3 years of extended follow-up in a phase II trial.

PURPOSE: To evaluate the long-term outcomes and molecular correlates of response after immediate preoperative intravesical chemotherapy (IPeIC) with mitomycin-C (MMC) in patients with non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS: In this single-center, open-label, randomized phase II trial, 33 patients received two split doses of IPeIC/MMC (40 mg/20 mL), whereas 38 patients underwent transurethral resection of bladder tumor (TURBT) alone. The primary endpoint was 3-year recurrence-free survival (RFS), and secondary endpoints included progression-free survival (PFS). Exploratory RNA sequencing was performed on IPeIC-treated patients (three with recurrence, 25 without) using a Monte Carlo-based resampling strategy. RESULTS: The median follow-up durations were comparable between the intervention (60.0 months) and control arms (60.4 months). IPeIC/MMC reduced recurrence risk by 76.8% versus TURBT alone (p=0.024), yielding a 3-year RFS rate of 90.7% versus 78.6%. On multivariable analysis, IPeIC/MMC independently improved RFS (hazard ratio [HR] 0.266, p=0.044). IPeIC was associated with superior PFS, with 3-year and 5-year rates of 100% versus 92.1% and 85.8%, respectively, in the controls (HR 0.078, p=0.014). Exploratory transcriptomics identified low Glutathione S-transferase Mu 1 (GSTM1) expression as the factor most strongly associated with recurrence. CONCLUSIONS: IPeIC/MMC is associated with improved long-term oncological outcomes compared with TURBT alone and represents a safe prophylactic option for patients with NMIBC who are unable to receive standard immediate postoperative intravesical chemotherapy because of safety concerns or practical constraints. The GSTM1 findings are hypothesis-generating and support future biomarker-driven validation studies.

Aged↗

PubMedDate not supplied

Micro-array analysis of the effect of post-transurethral bladder tumor resection urine on transforming growth factor-beta1 dependent gene expression in transitional cell carcinoma.

INTRODUCTION AND OBJECTIVES: Prior studies have shown that bladder trauma occurring during transurethral bladder tumor resection increases urinary levels of the cytokine transforming growth factor (TGF)-beta1. This study used complementary deoxyribonucleic acid micro-array technology to identify additional genes in human transitional cell carcinoma (TCC), whose expression is altered as a consequence of increased urinary levels of TGF-beta1. METHODS: The human TCC line 253J was cultured in standard media, or media spiked with either 10% post-transurethral bladder tumor resection urine (PTU), or PTU and anti-TGF-beta1 neutralizing antibody. Messenger ribonucleic acid from these conditions, together with messenger ribonucleic acid from stably transfected 253J cells over-expressing TGF-beta1, was hybridized with ATLAS micro-array membranes (Clontech, Palo Alto, CA) containing 588 human genes. Hybridization signal intensity was quantified using phospho-imaging. An analytic strategy based on the variance in the signal intensity ratio of specific housekeeping genes in control and experimental comparisons was used to identify significant changes in gene expression. Reverse transcriptase polymerase chain reaction of target genes was used to confirm gene over-expression and TGF-beta1 responsiveness. RESULTS: Seven genes were identified on micro-array: v-RAF-1, colony stimulating factor-1 receptor, v-FGR, insulin growth factor-1 receptor, epidermal growth factor receptor, alpha5 integrin, and interferon receptor-1. Reverse transcriptase polymerase chain reaction confirmed over-expression in the autocrine TGF-beta1 producing cell line and increased expression in response to exogenous TGF-beta1. CONCLUSIONS: TGF-beta1 in PTU alters the expression of multiple genes in human TCC in vitro. The impact of these changes on the biologic phenotype of the malignant cell and the efficacy of adjuvant therapies requires further evaluation.

Carcinoma, Transitional Cell↗

PubMed2001

[Ectopic prostatic tissue in retrotrigone of the bladder: a case report].

We herein report a case of ectopic prostatic tissue in the retrotrigone of the bladder. A 35-year-old man was referred to our hospital because of bladder tumor which was incidentally discovered on abdominal ultrasonography (US). US and computed tomography (CT) showed a tumor in the bladder wall 1.5 cm in diameter. Magnetic resonance imaging (MRI) revealed an invasive bladder tumor. Cystoscopy showed a non-papillary, wide-based tumor in the retrotrigone of the bladder. Transurethral resection of bladder tumor was carried out and pathological findings showed ectopic prostatic tissue. This is the 8th case of ectopic prostatic tissue in the Japanese literature.

Adult↗

PubMed2004

[Bladder hemangioma: a case report].

We report a case of a bladder hemangioma in a 30-year-old woman. She was admitted to our department with the chief complaints of gross hematuria and dysuria. Cystoscopy revealed a red sessiled tumor 5 mm in diameter on the right wall of the bladder. Transurethral resection of bladder tumor was performed on September 13, 2000. The specimen was pathologically diagnosed as cavenous hemangioma of the urinary bladder. Including our case, 85 cases of hemangioma of the bladder are reviewed in the Japanese literature.

Adult↗

PubMed2006

[A case report: Bilharzial schistosomiasis in the urinary bladder presented with gross hematuria].

A 31-year-old Japanese man who had been in Africa for two years presented with gross hematuria. He had been swimming in Lake Malawi during this period. Urinary specimen consisted of hematuria and pyuria. Cystoscopy showed tumors resembling Bilharzial tubercles located in the trigone, left lateral and posterior wall and dome. Further urine examination demonstrated eggs of schistosome haematobium. The patient was highly suspected of having Bilharzial schistosomiasis in the urinary bladder. Transurethral resection of bladder tumors was performed for diagnosis. Pathological examination revealed granuloma with many eggs of schistosome haematobium. He was diagnosed with Bilharzial schistosomiasis and was treated with 3,600 mg of praziquantel daily for two days. There have been no signs of recurrence during the one-year follow up except for excretion of degenerated eggs of schistosome haematobium in the urine specimens.

Adult↗

PubMed1998

[Kidney-sparing surgery for recurrent ureteral and bladder cancers in an aged patient with functionally solitary horseshoe kidney].

A 79-year-old woman was admitted with recurrent ureteral and bladder cancers. She had a horseshoe kidney with a non-functioning right renal unit. Fifteen months earlier, multiple urothelial tumors had first developed in the left upper ureter and bladder. Transurethral resection of bladder tumor (TUR-Bt) and partial ureterectomy (2 cm) had been performed. Presently, the recurrent tumors were located at the left lower ureter and bladder. Considering the high age of the patient, TUR-Bt and partial ureterectomy (5 cm) were performed. Besides urothelial cancers, she had been operated for carcinomas of the colon, uterus and stomach. Kidney-sparing therapy has successfully maintained her quality of life.

Aged↗

PubMed1981

Thigh adductor contraction during transurethral resection of bladder tumours: evaluation of inactive electrode placement and obturator nerve topography.

Thigh adductor contraction occurred in 17 of 160 patients during transurethral resection of newly diagnosed bladder tumours. In 13 of the 17 patients contractions were abolished by changing the site of the inactive electrode from the buttocks to the thigh. The topographic relationship between the obturator nerve and the bladder wall studied radiographically and at autopsy showed that the distance between the bladder and the nerve considerably diminished with increasing bladder volume. Thus, when obturator nerve stimulation occurs during transurethral resection transposition of the inactive electrode from the buttocks to the thigh should be tried first to prevent further stimulation. Moreover, TUR at low bladder volume may reduce the frequency of obturator nerve stimulation.

Electrodes↗

PubMed1997

A new technique for transurethral resection of bladder tumors: rotational tumor resection using a new arched electrode.

PURPOSE: A new technique of transurethral resection of bladder tumors is described. MATERIALS AND METHODS: A 2.5 cm. papillary, sessile bladder tumor was treated via a rotational resection technique with a new arched electrode to replace longitudinal resection using a conventional loop electrode. RESULTS: This method was easy to perform and allowed for en bloc resection of bladder tumor. CONCLUSIONS: This rotational resection technique is useful for evaluation of pathological depth of tumors in resected specimens.

Aged↗

PubMed1991

[Urinary cytology studied during 10 days after transurethral resection of bladder tumour and its relation to tumour recurrence].

Whether or not recurrence is related to the results of urinary cytology examined within 10 days after transurethral resection of bladder tumour was studied retrospectively in 47 patients with superficial bladder tumour. Of 7 cases with positive cytology during the postoperative 10 day period, 4 cases had a later recurrence of tumour and 2 cases had a residual tumour due to incomplete resection of original tumour. By microscopic chromocystoscopy, in 11 patients concurrent urothelial atypia (carcinoma in situ or dysplasia) was found in the apparently normal mucosa. Nine of the 11 cases had a later recurrence of tumour or a residual tumour. Of in total 15 patients combined with abnormal cytology and concurrent urothelial atypia, 12 (80%) were found with recurrence of tumor cystoscopically 4 approximately 64 months (mean; 20.6 months) after TUR. This recurrence rate was significantly (p less than 0.05) higher than that (42.4%) in patients without positive cytology and concurrent urothelial atypia. These results suggest that positive urinary cytology during 10 days subsequent to TUR and/or association with concurrent urothelial atypia are indicative of later tumour recurrence, incomplete resection of tumour or presence of additional occult tumour foci.

Humans↗

PubMed1982

[Advances in transurethral resection of bladder carcinoma (author's transl)].

Improved technical conditions and progress in the standardization of staging with consistent consideration of the pathohistological grading have produced conditions which allow to adapt the transurethral resection of bladder carcinoma to the principles of tumor surgery. Therefore a prospect of cure in spite of avoiding mutilating measures can be offered to the patient with low T-category of the tumor. Precondition is the consequent application of a strict resection strategy which is adapted to the tumor and provides exact statements of the area of tumor spread and its infiltration. In a period of 5 years 207 patients with stage T3--T3 tumors were treated primarily by means of differentiated, several times repeated TUR. The corrected 3 years survival rate of altogether 146 patients was 96% for stage Ta, 70% for stage T1, 54% for T2 and 48% for T3. Proceeding from our own results the methodology, indications and limitations of the transurethral resection technique are outlined and progressive measures discussed.

Electrosurgery↗

PubMed1994

Intravesical antitumor therapy immediately after transurethral resection of bladder cancer.

Patients with superficial transitional cell cancer of the urinary bladder were entered into a randomized trial to compare the effects of immediate and short-term postoperative instillation of peplomycin sulfate with simple irrigation. Although the recurrence-free rate of the 46 peplomycin-treated patients was lower, the difference was not significant. Repeated washing of the bladder at the end of transurethral resection might partly replace the role of cytotoxic therapy.

Administration, Intravesical↗

PubMed1996

Staging with computed tomography, transrectal ultrasonography and transurethral resection of bladder tumour: comparison with final pathological stage in invasive bladder carcinoma.

OBJECTIVE: To assess the accuracy of clinical staging methods in patients with locally advanced bladder cancer. PATIENTS AND METHODS: Sixty-five patients with invasive bladder cancer primarily staged using transrectal ultrasonography (TRUS), computed tomography (CT) and transurethral resection of the bladder tumour (TURBT) were compared with the final pathological stage determined after radical cystectomy. RESULTS: Accurate staging was obtained by TRUS, CT and TURBT in 40, 35 and 46% of the patients, respectively. The rank correlation between primary clinical stage and final pathological stages was significant by all three methods, but not close. CONCLUSIONS: The results of this study raise doubts about the assumed benefit of TRUS and CT in the clinical staging of invasive bladder tumours. These methods did not improve the findings obtained by TURBT alone.

Adult↗

PubMed1987

[Long-term intravesical treatment with adriamycin in chemoprevention of recurrence of transurethrally resected urinary bladder cancers].

64 patients with a histologically verified urothelial tumour of the urinary bladder were given intravesical Adriamycin-instillations after transurethral resection of their tumours. 34 patients received 50 mg Adriamycin once weekly for a period of 6 weeks. 30 patients, after undergoing this initial treatment, were treated with 50 mg Adriamycin once a month over a period of 2 years. After 1 year we found a relapse rate in the group with a long term therapy as compared with the first group a relapse rate of 32%. After 2 years of observation the relapse rate was practically the same in both groups (41% and 40%).

Administration, Intravesical↗

PubMed1999

The impact of transurethral resection of bladder tumour on serum levels of soluble E-cadherin.

OBJECTIVE: To evaluate soluble E-cadherin (sE-cadherin) as a potential tumour marker in patients with transitional cell carcinoma (TCC) of the bladder (previously shown to correlate with tumour grade, number of Ta/T1 tumours at presentation and a positive 3-month check cystoscopy) by assessing its serum concentration in relation to transurethral resection of bladder tumour (TURBT). PATIENTS AND METHODS: Samples of venous blood were obtained from 25 patients with bladder cancer: (i) before cystoscopy/TURBT: (ii) intraoperatively, during tumour resection; and (iii) on the first day after surgery. Levels of sE-cadherin were measured using an enzyme-linked immunosorbent assay. RESULTS: Sixty-three serum samples from patients with TCC of the bladder were available for analysis (23 before, 21 during and 19 after surgery). Patients with G2/3 tumours had significantly higher median preoperative levels of sE-cadherin (16.37 and 13.03 microg/mL, respectively) than those with G1 tumours (9.493 microg/mL; P = 0.0164). There was no correlation between tumour stage and preoperative sE-cadherin concentration. The median concentrations of sE-cadherin were not significantly different before, during and after TURBT. CONCLUSIONS: This study confirmed the previous finding that higher levels of serum sE-cadherin correlate with increasing tumour grade but not with clinicopathological stage. Serum sE-cadherin levels are not significantly altered by TURBT in the immediate perioperative period.

Adult↗

PubMed1998

[Three cases of the nephrogenic adenoma of the bladder].

Nephrogenic adenoma is a rare, benign tumor of the urinary tract. The origin of this tumor is supposed to be a metaplastic transformation of urothelium in response to stimulation such as recurrent urinary tract infections or surgical trauma. We experienced three cases of nephrogenic adenoma originating in the bladder. The first patient was a 29-year-old man with right vesicoureteral reflux (VUR). When Teflon injection for VUR was performed, a papillary tumor was found on the right wall of the bladder. Transurethral resection of the bladder tumor (TUR-Bt) was performed. The second patient was a 72-year-old woman who was suffering from chronic cystitis. Although she was treated with antibiotics for one year, the symptoms were not improved. Cystoscopy showed multiple papillary tumors at the retrotrigonum of the bladder and TUR-Bt was performed. The third patient was a 75-year-old man who had a history of the left pelvic and bilateral ureteral tumors. Left radical nephroureterectomy and right radical ureterectomy with an ileal graft replacement was performed. Three years later, cystoscopy demonstrated a papillary tumor at the retrotrigonum, which was resected transurethrally. Our cases are the 20th to 22nd cases of the nephrogenic adenoma of the bladder reported in the Japanese literature.

Adenoma↗

PubMed2001

Pedunculated prolapsing bladder hematoma (pseudotumor) mimicking an anterior vaginal polyp--a clinical curiosity and rare complication of transurethral resection of bladder tumor.

A young woman who presented with a recurrent bladder tumor was detected on follow up to be harboring a prolapsed bladder tumor at the external urinary meatus mimicking an anterior vaginal polyp. Excision and histopathological examination revealed an organized hematoma (pseudotumor). The literature regarding this clinical curiosity and its differential diagnosis is reviewed and discussed.

Adult↗